1. Home
  2. APRE vs GITS Comparison

APRE vs GITS Comparison

Compare APRE & GITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • GITS
  • Stock Information
  • Founded
  • APRE 2006
  • GITS 2018
  • Country
  • APRE United States
  • GITS South Korea
  • Employees
  • APRE N/A
  • GITS N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • GITS
  • Sector
  • APRE Health Care
  • GITS
  • Exchange
  • APRE Nasdaq
  • GITS Nasdaq
  • Market Cap
  • APRE 8.3M
  • GITS 7.0M
  • IPO Year
  • APRE 2019
  • GITS N/A
  • Fundamental
  • Price
  • APRE $1.47
  • GITS $2.07
  • Analyst Decision
  • APRE Strong Buy
  • GITS
  • Analyst Count
  • APRE 1
  • GITS 0
  • Target Price
  • APRE $20.00
  • GITS N/A
  • AVG Volume (30 Days)
  • APRE 40.4K
  • GITS 16.8K
  • Earning Date
  • APRE 11-06-2025
  • GITS 11-19-2025
  • Dividend Yield
  • APRE N/A
  • GITS N/A
  • EPS Growth
  • APRE N/A
  • GITS N/A
  • EPS
  • APRE N/A
  • GITS N/A
  • Revenue
  • APRE $841,012.00
  • GITS $29.00
  • Revenue This Year
  • APRE N/A
  • GITS N/A
  • Revenue Next Year
  • APRE N/A
  • GITS N/A
  • P/E Ratio
  • APRE N/A
  • GITS N/A
  • Revenue Growth
  • APRE N/A
  • GITS N/A
  • 52 Week Low
  • APRE $1.37
  • GITS $0.87
  • 52 Week High
  • APRE $5.01
  • GITS $9.78
  • Technical
  • Relative Strength Index (RSI)
  • APRE 45.12
  • GITS 38.31
  • Support Level
  • APRE $1.46
  • GITS $2.21
  • Resistance Level
  • APRE $1.57
  • GITS $2.47
  • Average True Range (ATR)
  • APRE 0.08
  • GITS 0.14
  • MACD
  • APRE 0.01
  • GITS -0.03
  • Stochastic Oscillator
  • APRE 54.45
  • GITS 2.97

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About GITS Global Interactive Technologies Inc. Common Stock

Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.

Share on Social Networks: